NCT04491695 (TREND) is a Phase 2, PHASE3 clinical trial of Tirofiban Hydrochloride in Acute Stroke, sponsored by Capital Medical University.

Who is sponsoring NCT04491695?

NCT04491695 is sponsored by Capital Medical University.

What drugs are being tested in NCT04491695?

Interventions in NCT04491695: Tirofiban Hydrochloride, Oral antiplatelet.

What condition does NCT04491695 study?

NCT04491695 studies Acute Stroke.

Is NCT04491695 still recruiting?

NCT04491695 is currently status unknown. Last updated 19 July 2022.

Last reviewed 2022-07-19 · How we verify

NCT04491695: TREND

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tirofiban for the Prevention of Neurological Deterioration in Acute Ischemic Stroke

Status unknown Phase 2, PHASE3 Last updated 19 July 2022

What this trial tests

Phase 2, PHASE3 trial testing Tirofiban Hydrochloride in Acute Stroke in 420 participants. Status unknown.

Timeline

12 September 2020

Primary endpoint
31 December 2022

31 March 2023

Quick facts

Lead sponsor	Capital Medical University
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	420
Start date	12 September 2020
Primary completion	31 December 2022
Estimated completion	31 March 2023
Sites	19 locations across China

Drugs / interventions tested

Tirofiban Hydrochloride — full drug profile →
Oral antiplatelet — full drug profile →

Conditions studied

Acute Stroke — all drugs for Acute Stroke →

Sponsor

Capital Medical University

Who can join

Adults 18 to 80, any sex, with Acute Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Currently, dual antiplatelet therapy with aspirin and clopidogrel (with loading doses) is widely used for patients with acute ischemic stroke. However, immediate, potent and reversible inhibition of platelet aggregation is not possible. Additionally, more than 5% patients have aspirin resistance and more than 15% patients have clopidogrel resistance. Therefore, an intravenously administered GPIIb/IIIa receptor inhibitor (Tirofiban) receptor blocker with fast onset and offset of actions will provide more desired antiplatelet effects in the setting of acute ischemic stroke, especially in patients with high risk of neurological deterioration. This study will measure the anti-platelet effects of Tirofiban in patients with acute ischemic stroke who had high risk of neurological deterioration.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Effects of Tirofiban on Neurological Deterioration in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial.
Zhao W, Li S, Li C, Wu C, et al · · 2024 · cited 42× · PMID 38648030 · DOI 10.1001/jamaneurol.2024.0868
Safety and efficacy of tirofiban in preventing neurological deterioration in acute ischemic stroke (TREND): Protocol for an investigator-initiated, multicenter, prospective, randomized, open-label, masked endpoint trial.
Wang J, Li S, Li C, Wu C, et al · · 2024 · cited 8× · PMID 39036300 · DOI 10.4103/bc.bc_93_23
Effects of tirofiban in preventing neurological deterioration in acute ischemic stroke with intracranial artery stenosis: A post hoc analysis of the TREND Trial.
Wang J, Qiao Y, Li S, Li C, et al · · 2025 · cited 3× · PMID 39950764 · DOI 10.1177/23969873251319151
Impact of Prestroke Antiplatelet Therapy on the Efficacy of Intravenous Tirofiban at Preventing Early Neurological Deterioration: A Prespecified Subgroup Analysis of the TREND Trial.
Wang J, Qiao Y, Li S, Li C, et al · · 2026 · PMID 41559328 · DOI 10.1007/s40256-025-00786-1

Verify or expand the search:

Other trials of Tirofiban Hydrochloride

Trials testing the same drug.

NCT06587347 — Tirofiban for the Prevention of Early Neurological Deterioration After Intravenous Thrombolysis in Acute Ischemic Stroke · Phase 2, PHASE3 · not yet recruiting
NCT05604638 — Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke · Phase 3 · recruiting
NCT04818944 — Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke · Phase 1, PHASE2 · withdrawn
NCT03406832 — Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI · NA · unknown
NCT03406819 — Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI · NA · unknown

Other recruiting trials for Acute Stroke

Currently open trials in the same condition.

NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
NCT07295366 — Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Cont · Phase 4 · recruiting
NCT07355881 — mSOAR and Early Mortality in Acute Stroke · recruiting
NCT07301372 — Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemi · Phase 4 · recruiting
NCT07167550 — The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke · Phase 3 · recruiting

Other Capital Medical University trials

Trials by the same sponsor.

NCT07379437 — Haematococcus Pluvialis Astaxanthin for Brain Aging · NA · not yet recruiting
NCT07531394 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic St · Phase 3 · not yet recruiting
NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07513233 — Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL) · Phase 1 · not yet recruiting
NCT07495358 — Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cance · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04491695 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Capital Medical University
Last refreshed: 19 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04491695.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing